A comparative assessment of the efficacy and side-effect liability of neuroprotective compounds in experimental stroke.
about
Neuroprotection for ischemic stroke: past, present and futureNovel NMDA receptor modulators: an updateGlutamate receptor ion channels: structure, regulation, and functionDrug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery.Implications of gliotransmission for the pharmacotherapy of CNS disorders.Why do neuroprotective drugs that are so promising in animals fail in the clinic? An industry perspective.Context-dependent GluN2B-selective inhibitors of NMDA receptor function are neuroprotective with minimal side effects.Conantokin-G attenuates detrimental effects of NMDAR hyperactivity in an ischemic rat model of stroke.Drug therapies for stroke and traumatic brain injury often display U-shaped dose responses: occurrence, mechanisms, and clinical implications.The development of biomarkers to reduce attrition rate in drug discovery focused on oncology and central nervous system.Combined effect of rifampicin-induced P-glycoprotein expression and lipopolysaccharide-induced intestinal sepsis on the effective permeability and pharmacokinetics of an anti-malarial candidate CDRI 97/78 in rats.6-Formylpterin protects retinal neurons from transient ischemia-reperfusion injury in rats: a morphological and immunohistochemical study.Conotoxins: Therapeutic Potential and Application.Lipid-based nanocarrier efficiently delivers highly water soluble drug across the blood-brain barrier into brain.
P2860
Q24645185-B44CEA6F-B296-4418-B06E-44ABCC4F3A36Q26849614-A60F21AB-A6C2-4997-834B-3DCC2B2FAEB8Q28290774-76011CD0-3128-4426-9DF5-10B56208072FQ33946973-2EB2220F-3656-4215-A36C-ACC5C3935419Q33971765-C0365A7D-3C8B-4399-B30F-5188FA45E085Q34941187-7CE759A0-F4E4-4819-80A5-BE62F8987922Q35202428-251974C6-92A2-4D92-89AF-52B9702FB05BQ35589910-DE2FA443-18C2-40D4-B08F-B0683726F64DQ37211892-E197DBD8-8967-4119-B326-4DD2B1531DE2Q38907580-A5B8C0E5-5D54-4EE2-94C4-A7352864E966Q41394865-0D4E1528-39BA-4D92-86F5-0C708747BC24Q44626139-2F7471AC-6575-40F1-A3DE-DF13C9F7421EQ46364124-02DF2904-3C28-46EA-9FFE-CC6C5C639DF0Q48503723-E7409980-8247-4F4A-9BCC-FDF111C05D5C
P2860
A comparative assessment of the efficacy and side-effect liability of neuroprotective compounds in experimental stroke.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
A comparative assessment of th ...... pounds in experimental stroke.
@ast
A comparative assessment of th ...... pounds in experimental stroke.
@en
type
label
A comparative assessment of th ...... pounds in experimental stroke.
@ast
A comparative assessment of th ...... pounds in experimental stroke.
@en
prefLabel
A comparative assessment of th ...... pounds in experimental stroke.
@ast
A comparative assessment of th ...... pounds in experimental stroke.
@en
P2093
P1433
P1476
A comparative assessment of th ...... pounds in experimental stroke.
@en
P2093
P304
P356
10.1016/S0006-8993(00)03269-8
P407
P577
2001-02-01T00:00:00Z